The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
PolyPeptide Group AG (PolyPeptide) is a contract development and manufacturing organization (CDMO) that develops and commercializes generic peptides and peptide-related molecules. The company develops generic peptides, custom research-grade peptides, radiolabeled peptides and oligonucleotides. It provides services including pre-GMP development, inspection, quality control, regulatory support, process development and optimization. The company operates a global manufacturing network with facilities in Europe, the US, and India, targeting international markets. PolyPeptide is headquartered in Baar, Zug, Switzerland.PolyPeptide Group AG Key Recent Developments
- Dec 12, 2025: Lupin Manufacturing Solutions and Polypeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
- Dec 12, 2025: PolyPeptide and Lupin Manufacturing Solutions Form Alliance to Strengthen Peptide Supply for Metabolic Therapies
- Oct 28, 2025: Lifecore and PolyPeptide Collaborate on End-to-End Peptide Manufacturing Solution for U.S. Market
- Oct 28, 2025: Lifecore and PolyPeptide Collaborate to Provide End-to-End Peptide Manufacturing Solution for U.S. Market
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lonza Group Ltd
- Senn Chemicals AG
- BCN Peptides SA
- Bachem AG
- AmbioPharm Inc

